Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Blood test set to reduce late detection of lung cancer
Read more https://t.co/x5AiRBU19x cc @OncimmuneECDT
#industrynews #findings #bloodtest #detection #lungcancer #EarlyCDT #lungtest #clinicaldiagnosis #platformtechnology #technology
The first BTOG essential update conference to have a waiting list, demonstrating the high interest in lung cancer screening. #btoglcscreening @OncimmuneECDT
Oncimmune Chief Medical Officer, Professor James Jett presents highlights from the Early detection of Cancer of the Lung Scotland (ECLS) trial presented at #WCLC19 earlier this month @ClevelandClinic in Ohio, USA. #LungCancer #DetectCancerEarly
Interesting discussion of earlier intervention once new technologies can detect tumours earlier. If the tumour is too small to identify, can therapeutics help? #EDxConf19
Good morning from Stanford, California. We're entering the final day of an excellent few days at the Early Detection of Cancer Conference 2019 with @CR_UK @CanaryCenter @OHSUNews #EDxConf19 #DetectCancerEarly #LungCancer
At Oncimmune, we’re working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find lung cancer in its early stages.
#WorldLungDay #LungCancer #DetectCancerEarly #ImmuneSystem
Delighted to make it to the top 5 of #MidlandsTech50. Thank you to @BCloudUK
#DetectCancerEarly #LungCancer #ImmuneSystem
BusinessCloud.co.uk on Twitter
“🎉Today we can reveal our first #MidlandsTech50 ranking! 🎉 Congratulations to all those who made the top 50 and especially to #AR firm @E...
twitter.com
Senior appointments at Midlands MedTech @OncimmuneECDT https://t.co/ZvC3cJ44r8
Gallery
